Title: A General Audit of Adenocarcinoma Lung Cases Treated At JK Cancer Institute Kanpur between January 2018 to December 2019
Authors: Md Aqueel, Mayank Kumar Gautam, S.N. Prasad, M W Raza, Pramod Kumar Singh
DOI: https://dx.doi.org/10.18535/jmscr/v8i10.03
Abstract
Introduction: Lung adenocarcinoma is a subtype of non-small cell lung cancer (NSCLC). Lung adenocarcinoma is categorized as such by how the cancer cells look under a microscope. Lung adenocarcinoma starts in glandular cells, which secrete substances such as mucus, and tends to develop in smaller airways, such as alveoli(1,2,3,4). Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR)(5). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers (NSCLC) obtaining objective response when treated with gefitinib harbour activating mutations in the EGFR gene. Consequently, EGFR mutation has been widely studied, together with other molecular characteristics, as a potential predictive factor for gefitinib efficacy(6,7,8,9,10,11)
Aim: To Compare the overall survival, time to disease progression and toxicity between two chemotheraupetic regimen.
Material And Methods: Single institution retrospective study 2018, 2019 in patients who received gefitinib, gemcitabine+cisplatin, gemcitabine+carboplatin, paclitaxel+carboplatin based chemotheraupetic regimen. A total 75 patients were identified. of whom 19 patients received tab gefitinib,7 received pacli+carbo,1 received RT f/b pacli+carbo,1 patient received pacli+carbo f/b RT,2 patient received pacl+carbo f/b gefitinib,6 patient received gem+carb f/b gefitinib,2 received palliative RT f/b gefitinib,1 patient received gefitinib f/b methotrexate,1 patient received gefitinib f/b pacli+carbo,3 patient received gefitinib f/b RT,1 patient received gem+cis,1 patient received gem+cis f/b gem+carb,1 patient received gem+cis f/b gefitinib,1 patient received bevaci+gem+carb,1 patient received erlotinib,3 patient received palliative RT,1 patient received bevaci+gem+carb f/bgem+carb f/b pacli+carb f/b gem+carb f/b gefitinib
Results: We observed the overall survival, time to progression were better in gefitinib arm. No major acute toxicities seen in both arm
Conclusion: Gefitinib based chemotherapy provide better overall survival and increased time to disease progression and advantage of oral dosing thus facilitating drug delivery and patient compliance
Keywords: Gefitinib, adenocarcinoma lung.
